Business Information
The group's principal activities are to develop pharmaceutical and diagnostic products. The group concentrates the product discovery and development efforts in two principal areas, infectious diseases caused by bacterial and fungal pathogens and human diseases believed to have a significant genetic component. The group has ten ongoing product development programs. Its product candidate, ramoplanin, is in phase iii clinical trials for the prevention of bloodstream infections caused by vancomycin-resistant enterococci. It also has six product discovery and development alliances with pharmaceutical companies astrazeneca, biomerieux, schering-plough and wyeth. The group also provides drug discovery services to genomevisiontm services, providing drug discovery services to pharmaceutical, biotechnology companies and national human genome research institute. The group operates solely in the domestic market. On 06-Feb-2004, the group acquired genesoft pharmaceuticals inc.
|
|
Name |
Title
|
Email
|
| David Stone | Chmn. | N/A | | Philippe Maitre | Sr. VP, CFO | N/A | | Aaron Berg | VP - Marketing | N/A | | Anthony Watkins | VP - Corporate Development | N/A | | Christopher Taylor | VP - Corporate Communications, Investor Relations | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 46,152 | (78,477) | | 2005 | 23,609 | (88,593) | | 2004 | 6,613 | (93,271)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
